Unlocking Hope: Innovative Approaches to Managing Behavioral Symptoms in Alzheimer's
"Exploring the clinical implications of pharmacotherapy for Behavioral and Psychological Symptoms of Dementia (BPSD) in Alzheimer's Disease (AD) and highlighting a potential shift in treatment strategies."
Alzheimer's disease (AD) is not only characterized by cognitive decline but also by a range of behavioral and psychological symptoms of dementia (BPSD). These symptoms, which include agitation, aggression, delusions, and hallucinations, significantly impact the quality of life for both patients and their caregivers. Finding effective ways to manage these symptoms is crucial, yet it remains a complex challenge.
In Japan, the treatment landscape for BPSD in AD presents unique challenges. While there's a pressing need for effective interventions, no medications are specifically approved for BPSD in AD. Atypical antipsychotics, often used to manage these symptoms, are prescribed cautiously due to concerns about increased mortality rates in elderly patients. This creates a therapeutic gap, urging clinicians to explore alternative strategies.
This article delves into a research perspective on the effects of aging and disease progression on BPSD. We'll explore how these factors influence the manifestation of behavioral symptoms, potentially guiding more tailored and effective treatment approaches. By understanding these dynamics, we aim to shed light on innovative pharmacotherapy strategies that could improve the lives of those living with Alzheimer's disease.
U.S. Care Setting Figures
The CDC FastStats page gives 2020 U.S. figures of 24.7% for adult day services center participants, 42.1% for residential care community residents, and 35.6% for home health agency patients. The figures are attributed to the Biennial Overview of Post-acute and Long-term Care in the United States, Table 4. The page also lists related data on variation in adult day services participant characteristics by center ownership.
Diagnostic Guidance and Its Reach
Clinical diagnosis of cognitive impairment and the presence of Alzheimer’s disease biomarkers are important issues for early and adequate treatment. A 2024 U.S. clinical practice guideline describes existing diagnostic guidelines as decades old and aimed at specialists. The APA guidelines focus on assessing dementia and age-related cognitive decline in clinical practice, noting that although dementia and MCI can occur under age 65, most cases occur in older adults.
Milestones in Alzheimer’s History
The Alzheimer’s Association reports that Alzheimer’s disease was first described in 1906. It identifies the Association’s founding in 1980 as a milestone in advancing research. A historical review also examines the naming of Alzheimer’s disease and notes that perceptions of dementia symptoms have existed throughout human history.
Understanding the Impact of Aging and Disease Progression on BPSD
To investigate how aging and disease progression affect BPSD in AD, researchers conducted a study involving patients referred for AD evaluation due to their behavioral symptoms. The study carefully looked at various factors, including age, education level, cognitive function, and the severity of dementia. Cognitive function was assessed using the Mini-Mental State Examination (MMSE), while BPSD were evaluated using the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD).
- Younger Patients (YG): Clear separation between mood, psychotic, and behavioral clusters.
- Older Patients (OG): Psychotic symptoms and anxiety/phobias merge. Aggression and affective disturbances combine.
- Higher Performance Group (HPG): Similar to younger patients, distinct symptom clusters.
- Lower Performance Group (LPG): Psychotic symptoms and mood disturbances/aggression combine.
FDA Approval for Agitation
The FDA announced supplemental approval of Rexulti (brexpiprazole) oral tablets for agitation associated with dementia due to Alzheimer’s disease. The agency describes it as the first FDA-approved treatment option for this indication. The approval is specifically for agitation associated with Alzheimer’s-related dementia.
Treatment and Translation Challenges
A 2022 article on failed Alzheimer’s clinical trials describes the disease as progressive and says existing causal theories focus on amyloid beta plaques and neurofibrillary tau tangles. A 2026 review reports that current therapies provide limited clinical benefit despite advances in understanding mechanisms such as amyloid-beta accumulation, tau pathology, and neuroinflammation. The review also points to difficulty translating this understanding into effective therapies.
Dementia and Alzheimer’s Are Not Synonyms
Dementia is a general term for a decline in mental ability severe enough to interfere with daily life, whereas Alzheimer’s is a specific disease. Alzheimer’s is the most common type of dementia, but other conditions can also cause significant cognitive decline. Symptoms across dementia types can be very similar, especially in early stages.
Implications for Treatment: A New Perspective on BPSD
The research suggests that BPSD in AD may share similarities with bipolar disorder or psychotic depression, particularly in later stages. This perspective opens doors to considering medications typically used for mood stabilization or augmentation of antidepressants, rather than solely relying on antipsychotics. This approach aligns with the need to minimize the use of antipsychotics due to their associated risks in elderly patients.
Regional Expert Perspectives
An expert panel from Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia, and Slovenia discussed Alzheimer’s diagnostics, general management, and treatment. The report says these Central and Eastern European countries represent around 88 million people. The panel’s stated aim included estimating Alzheimer’s prevalence and confirming the presence of the disease.
Global Burden and Future Projections
A 2025 Lancet article reports that 55 million people worldwide live with dementia, with Alzheimer’s disease accounting for 50–70% of cases. It says around 69 million people with mild cognitive impairment due to Alzheimer’s disease will develop dementia within a few years. The article projects that dementia numbers will triple by 2050, given ageing populations and current risk-factor trends.
Putting Care Innovations into Practice
The NIA’s 2021–2022 scientific advances page describes the IMPACT Collaboratory as offering growing support for real-world dementia-care innovators. It identifies a major challenge as finding effective innovations and delivering them in real-world situations and health care settings. The challenge concerns care for people living with Alzheimer’s and related dementias as well as their care partners.